Flecainide acetate (flecainide): Reviews and patient testimonials

Flecainide acetate 100 mg Tablets

Flecainide acetate is indicated for use in patients with the following arrhythmias:

Severe symptomatic supraventricular arrhythmia

AV nodal reciprocating tachycardia.

Arrhythmias associated with the Wolff-Parkinson-White syndrome and similar conditions associated with the presence of accessory pathways.

Paroxysmal atrial fibrillation in patients with disabling symptoms after cardioversion.

Patients with structural heart disease and/or impaired left ventricular function should be excluded because of the increased risk of pro-arrhythmic effects. Arrhythmias of recent onset will respond more readily.

Symptomatic sustained ventricular tachycardia.

Premature ventricular contractions and/or non-sustained ventricular tachycardia which are causing disabling symptoms which have failed to respond to other forms of therapy or in which other treatments have not been tolerated.

Flecainide tablets can be used for the maintenance of normal rhythm following conversion by other means.

Flecainide Acetate 100 mg tablets

• Treatment of AV nodal reciprocating tachycardia; arrhythmias associated with Wolff-Parkinson-White Syndrome and similar conditions with accessory pathways, when other treatment has been ineffective.

• Treatment of severe symptomatic and life-threatening paroxysmal ventricular arrhythmia which has failed to respond to other forms of therapy or where other treatments have not been tolerated.

• Treatment of paroxysmal atrial arrhythmias (atrial fibrillation, atrial flutter and atrial tachycardia) in patients with disabling symptoms after conversion provided that there is definite need for treatment on the basis of severity of clinical symptoms, when other treatment has been ineffective. Structural heart disease and/or impaired left ventricular function should be excluded because of the increased risk for pro-arrhythmic effects.

Flecainide Acetate 50 mg tablets

• Treatment of AV nodal reciprocating tachycardia; arrhythmias associated with Wolff-Parkinson-White Syndrome and similar conditions with accessory pathways, when other treatment has been ineffective.

• Treatment of severe symptomatic and life-threatening paroxysmal ventricular arrhythmia which has failed to respond to other forms of therapy or where other treatments have not been tolerated.

• Treatment of paroxysmal atrial arrhythmias (atrial fibrillation, atrial flutter and atrial tachycardia) in patients with disabling symptoms after conversion provided that there is definite need for treatment on the basis of severity of clinical symptoms, when other treatment has been ineffective. Structural heart disease and/or impaired left ventricular function should be excluded because of the increased risk for pro-arrhythmic effects.

Flecainide acetate 50 mg Tablets

Flecainide acetate is indicated for use in patients with the following arrhythmias:

Severe symptomatic supraventricular arrhythmia

AV nodal reciprocating tachycardia.

Arrhythmias associated with the Wolff-Parkinson-White syndrome and similar conditions associated with the presence of accessory pathways.

Paroxysmal atrial fibrillation in patients with disabling symptoms after cardioversion.

Patients with structural heart disease and/or impaired left ventricular function should be excluded because of the increased risk of pro-arrhythmic effects. Arrhythmias of recent onset will respond more readily.

Symptomatic sustained ventricular tachycardia.

Premature ventricular contractions and/or non-sustained ventricular tachycardia which are causing disabling symptoms which have failed to respond to other forms of therapy or in which other treatments have not been tolerated.

Flecainide tablets can be used for the maintenance of normal rhythm following conversion by other means.

Flecainide Acetate Tablets 100mg

• Treatment of AV nodal reciprocating tachycardia; arrhythmias associated with Wolff-Parkinson-White Syndrome and similar conditions with accessory pathways, when other treatment has been ineffective.

• Treatment of severe symptomatic and life-threatening paroxysmal ventricular arrhythmia which has failed to respond to other forms of therapy or where other treatments have not been tolerated.

• Treatment of paroxysmal atrial arrhythmias (atrial fibrillation, atrial flutter and atrial tachycardia) in patients with disabling symptoms after conversion provided that there is definite need for treatment on the basis of severity of clinical symptoms, when other treatment has been ineffective. Structural heart disease and/or impaired left ventricular function should be excluded because of the increased risk for pro-arrhythmic effects.

Flecainide Acetate Tablets 50mg

• Treatment of AV nodal reciprocating tachycardia; arrhythmias associated with Wolff-Parkinson-White Syndrome and similar conditions with accessory pathways, when other treatment has been ineffective.

• Treatment of severe symptomatic and life-threatening paroxysmal ventricular arrhythmia which has failed to respond to other forms of therapy or where other treatments have not been tolerated.

• Treatment of paroxysmal atrial arrhythmias (atrial fibrillation, atrial flutter and atrial tachycardia) in patients with disabling symptoms after conversion provided that there is definite need for treatment on the basis of severity of clinical symptoms, when other treatment has been ineffective. Structural heart disease and/or impaired left ventricular function should be excluded because of the increased risk for pro-arrhythmic effects.

Route of administration: Oral
Molecule: flecainide